Merck axes two of nine ADCs in pact with Kelun-Biotech

23 Oct 2023
endpts.com
ADCPhase 3
Merck has chosen not to pick up two preclinical antibody-drug conjugates from its partner Sichuan Kelun-Biotech, the Chinese drugmaker disclosed Monday.
The termination does not affect three clinical-stage ADCs that the companies are developing, including the Phase III breast and lung cancer asset SKB-264/MK-2870, Kelun said. Four other preclinical programs also remain in the deal.
Merck has made multiple pacts with Kelun since May 2022, promising as much as $12 billion across three deals for up to nine ADCs. With the small pullback announced Monday, Kelun saw its shares dip about 7%.
Merck axes two of nine ADCs in pact with Kelun-Biotech
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.